Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported preliminary unaudited net revenues of approximately $28.4 million for Q4 2022, totaling $134.0 million for the full year. Net product revenues were around $28.3 million and $103.5 million respectively. The company reiterates its 2023 net product revenue guidance forecast of $120-$140 million. As of December 31, 2022, Aurinia held approximately $388.7 million in cash and equivalents. The number of patients on LUPKYNIS therapy increased to 1,525 by year-end.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that Peter Greenleaf, CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 4:30 p.m. PT in San Francisco, CA. Interested parties can listen to the live audio webcast on the Aurinia corporate website under the 'News/Events' section. Aurinia is dedicated to developing therapies for serious diseases, having launched LUPKYNIS®, the first FDA-approved oral treatment for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals (NASDAQ: AUPH) and Sun Pharmaceuticals have reached a settlement regarding patent infringement claims related to Sun's CEQUA^® product. The settlement includes a joint motion to dismiss an Inter Partes Review of Aurinia's U.S. Patent No. 10,286,036. This agreement is contingent on the U.S. Patent Trial and Appeal Board terminating the Inter Partes Review. Both companies will cease further claims against each other under this settlement.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced the grant of inducement stock options and restricted stock units (RSUs) to two new employees. A total of 36,220 stock options were issued, with an exercise price of $5.10, alongside 22,120 RSUs, all dated December 5, 2022. The options vest over three years, while the RSUs vest in equal annual installments over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support the company's mission in autoimmune disease therapeutics.

Aurinia Pharmaceuticals has received marketing authorization for LUPKYNIS (voclosporin) from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with active lupus nephritis (LN). This approval follows the European Commission's authorization on September 19, 2022, highlighting the drug's promising phase 3 clinical trial outcomes. LUPKYNIS is the first oral medication approved in both the U.S. and Europe for LN, aiming to improve treatment accessibility for patients.

Aurinia Pharmaceuticals announced Q3 2022 net revenue of $55.8 million, up from $14.7 million in Q3 2021. The revenue includes a $30 million milestone from Otsuka for LUPKYNIS® approval in Europe. The company adjusted its revenue guidance for 2022 to $100-105 million and projected $120-140 million for 2023. As of October 31, 2022, Aurinia reported approximately $400 million in cash and equivalents. Despite a slight decline in new patient start forms, the company achieved significant progress in commercialization and patient adherence.

Aurinia Pharmaceuticals announced it will release its third quarter 2022 financial and operational results on November 3, 2022, before market opening. The company’s management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. Participants can join the call by dialing 877-407-9170 (U.S. and Canada) or via the company’s website. Aurinia is known for its FDA-approved treatment LUPKYNIS® for lupus nephritis, aiming to meet high medical needs in targeted patient populations.

Aurinia Pharmaceuticals (NASDAQ:AUPH) announced that data from various studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2022 in Orlando, Florida, from November 3-6. The presentations will highlight LUPKYNIS's long-term safety and efficacy in treating active lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE). Notable studies include efficacy over three years and a prospective registry of patients treated with voclosporin.

Aurinia Pharmaceuticals (NASDAQ:AUPH) announced the granting of inducement stock options and restricted stock units (RSUs) to four new employees. A total of 20,800 stock options priced at $7.52 per share and 12,500 RSUs were granted, effective October 3, 2022. The stock options vest over three years, with one-third vesting after one year, while the RSUs vest in three annual installments. This opportunity is aligned with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent critical to the company’s mission of addressing autoimmune diseases.